PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE
申请人:Nocion Therapeutics, Inc.
公开号:US20210128589A1
公开(公告)日:2021-05-06
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:
The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
[EN] ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE<br/>[FR] BLOQUEURS DE CANAUX IONIQUES SUBSTITUÉS PAR UN ESTER ET MÉTHODES D'UTILISATION
申请人:NOCION THERAPEUTICS INC
公开号:WO2020185915A1
公开(公告)日:2020-09-17
The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
Compounds and compositions having anti-inflammatory and analgesic
申请人:The Procter & Gamble Company
公开号:US05013759A1
公开(公告)日:1991-05-07
Substituted phenylacetic acid amide compounds, and pharmaceutically-acceptable salts thereof, of the formula: ##STR1## wherein X is O or S; R.sub.1 is H, OH or CH.sub.3 ; R.sub.2 is straight chain alkenyl, branched chain or cyclic hydrocarbon having from about 7 to about 24 carbon atoms; R.sub.3 is OH, OSO.sub.3.sup.-, OPO.sub.3.sup.-- or a short chain ester with from about 1 to about 6 carbon atoms.
Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
申请人:Singh Ulagaraj Chandra
公开号:US20080058362A1
公开(公告)日:2008-03-06
Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.
Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following enzymatic or chemical hydrolysis. In various embodiments, these esterified capsaicinoids have a higher lipophilicity, lipid solubility and result in less irritation to the stomach than the parent capsaicinoid, and hence may be included in certain dietary supplement formulations, including capsules, pills and tablets dietary supplement formulations. The dietary supplement compositions may be used for pain management in mammals in vivo and/or in the treatment of various pathological conditions in humans.